UNSPSC 51432505: Trandolapril

This classification denotes an ace inhibitor with the molecular formula C24H34N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1T0N3G9CRC, chemically known as 1h-indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-alpha,7a-beta))- but generally known as trandolapril, which bears US NIH Compound Identifier 5484727. European Medicines Agency schedules Trandolapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11212MIG.

UNSPSC 51432505 Trandolapril, a Commodity code, names a specific antihypertensive medication that state and local governments procure primarily as part of broader emergency medical services and pharmacy benefit program acquisitions. Recent solicitations show state and local buyers sourcing trandolapril and related medications through two distinct channels: direct procurement of emergency life support medications for fire rescue operations, and participation in cooperative multi-state pharmaceutical purchasing programs that aggregate demand across state agencies and local facilities. The code sits within larger medication and pharmaceutical supply chains where pricing, regulatory compliance, wholesaler relationships, and inventory management drive procurement strategy.

The issuing-body mix spans fire departments (the City of Tampa's Fire Rescue operation), state health and human services agencies (the Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (the Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities in Minnesota and Oregon). The Tampa Fire Rescue solicitation (Bid 26-P-00188, IFB, due April 8, 2026) sought four specific emergency medications including epinephrine, adenosine, labetalol, and diltiazem—all Advanced Life Support drugs delivered within ten calendar days with a nine-month minimum expiration guarantee and a firm one-year contract term with renewal options. The Minnesota MMCAP RFP (due March 26, 2026) established multistate contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026, and emphasis on cGMP and DSCSA compliance, EDI capability, and tiered pricing formats. The Texas HHS Commission's RFI (HHS0017013, due April 3, 2026) represents exploratory procurement seeking vendor capability to implement direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels. Activity is concentrated in the Southeast and Midwest, with the Tampa and Minnesota cooperative procurements representing recent concrete demand signals and the Texas RFI signaling emerging interest in direct-manufacturer pharmacy relationships.